Prolonged cortical silent period among drug-naive subjects at ultra-high risk of psychosis

Schizophrenia Research

Volumn 160, Issue 1-3, 2014, Pages 124-130

  Tang, Yingying ^a   Zhang, Tianhong ^a   Edelman, Bradley ^b   Zeng, Botao ^a   Zhao, Shanshan ^a   Li, Chunyan ^a   Zhuo, Kaiming ^a   Qian, Zhenying ^a   Li, Hui ^a   Guo, Qian ^a   Cui, Huiru ^a   Zhu, Yikang ^a   Jiang, Lijuan ^a   Li, Chunbo ^a   Yu, Dehua ^c   Wang, Jijun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b University of Minnesota   (United States)

^c TONGJI UNIVERSITY   (China)

Author keywords

Cortical inhibition; Cortical silent period; Schizophrenia; Short interval cortical inhibition; Ultra high risk of psychosis

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR;

ADULT; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL SILENT PERIOD; FACILITATION; FEMALE; HUMAN; INHIBITION (PSYCHOLOGY); INTRACORTICAL FACILITATION; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SHORT INTERVAL CORTICAL INHIBITION; TRANSCRANIAL MAGNETIC STIMULATION; COMPARATIVE STUDY; EVOKED MUSCLE RESPONSE; HEMISPHERIC DOMINANCE; MOTOR CORTEX; NERVE CELL INHIBITION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; RISK; SCHIZOPHRENIA; YOUNG ADULT;

ADULT; EVOKED POTENTIALS, MOTOR; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MOTOR CORTEX; NEURAL INHIBITION; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK; SCHIZOPHRENIA; TRANSCRANIAL MAGNETIC STIMULATION; YOUNG ADULT;

EID: 84928258970     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.10.004     Document Type: Article

References (59)

1. Bajbouj M., Lisanby S.H., Lang U.E., Danker-Hopfe H., Heuser I., Neu P. Evidence for impaired cortical inhibition in patients with unipolar major depression. Biol. Psychiatry 2006, 59(5):395-400.
2. Benes F.M. Model generation and testing to probe neural circuitry in the cingulate cortex of postmortem schizophrenic brain. Schizophr. Bull. 1998, 24(2):219-230.
3. Cannon T.D., Cadenhead K., Cornblatt B., Woods S.W., Addington J., Walker E., Seidman L.J., Perkins D., Tsuang M., McGlashan T., Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 2008, 65(1):28-37.
4. Carletti F., Woolley J.B., Bhattacharyya S., Perez-Iglesias R., Poli P.F., Valmaggia L., Broome M.R., Bramon E., Johns L., Giampietro V. Alterations in white matter evident before the onset of psychosis. Schizophr. Bull. 2012, 38(6):1170-1179.
5. Chen X.S., Li C.B., Smith R.C., Xiao Z.P., Wang J.J. Differential sensory gating functions between smokers and non-smokers among drug-naive first episode schizophrenic patients. Psychiatry Res. 2011, 188(3):327-333.
6. Choi J.-S., Chon M.-W., Kang D.-H., Jung M.H., Kwon J.S. Gender difference in the prodromal symptoms of first-episode schizophrenia. J. Korean Med. Sci. 2009, 24(6):1083-1088.
7. Choi H.C., Kim Y.I., Song H.K., Kim J.E., Kim D.S., Kang T.C. Effects of selective serotonin reuptake inhibitors on GABAergic inhibition in the hippocampus of normal and pilocarpine induced epileptic rats. Brain Res. 2010, 1357:131-141.
8. Daskalakis Z.J., Christensen B.K., Chen R., Fitzgerald P.B., Zipursky R.B., Kapur S. Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Arch. Gen. Psychiatry 2002, 59(4):347.
9. Daskalakis Z.J., Paradiso G.O., Christensen B.K., Fitzgerald P.B., Gunraj C., Chen R. Exploring the connectivity between the cerebellum and motor cortex in humans. J. Physiol. 2004, 557(Pt 2):689-700.
10. Daskalakis Z.J., Fitzgerald P.B., Christensen B.K. The role of cortical inhibition in the pathophysiology and treatment of schizophrenia. Brain Res. Rev. 2007, 56(2):427-442.
11. Daskalakis Z.J., Christensen B.K., Fitzgerald P.B., Moller B., Fountain S.I., Chen R. Increased cortical inhibition in persons with schizophrenia treated with clozapine. J. Psychopharmacol. 2008, 22(2):203-209.
12. Deisz R.A. GABA(B) receptor-mediated effects in human and rat neocortical neurones in vitro. Neuropharmacology 1999, 38(11):1755-1766.
13. Di Lazzaro V., Oliviero A., Saturno E., Dileone M., Pilato F., Nardone R., Ranieri F., Musumeci G., Fiorilla T., Tonali P. Effects of lorazepam on short latency afferent inhibition and short latency intracortical inhibition in humans. J. Physiol. 2005, 564(Pt 2):661-668.
14. Farzan F., Barr M.S., Sun Y., Fitzgerald P.B., Daskalakis Z.J. Transcranial magnetic stimulation on the modulation of gamma oscillations in schizophrenia. Ann. N. Y. Acad. Sci. 2012, 1265:25-35.
15. Fitzgerald P., Brown T., Daskalakis Z., DeCastella A., Kulkarni J. A study of transcallosal inhibition in schizophrenia using transcranial magnetic stimulation. Schizophr. Res. 2002, 56(3):199.
16. Fitzgerald P.B., Brown T.L., Daskalakis Z.J., Kulkarni J. A transcranial magnetic stimulation study of inhibitory deficits in the motor cortex in patients with schizophrenia. Psychiatry Res. 2002, 114(1):11.
17. Fusar-Poli P., Bonoldi I., Yung A.R., Borgwardt S., Kempton M.J., Valmaggia L., Barale F., Caverzasi E., McGuire P. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 2012, 69(3):220-229.
18. Fusar-Poli P., Borgwardt S., Bechdolf A., Addington J., Riecher-Rossler A., Schultze-Lutter F., Keshavan M., Wood S., Ruhrmann S., Seidman L.J., Valmaggia L., Cannon T., Velthorst E., De Haan L., Cornblatt B., Bonoldi I., Birchwood M., McGlashan T., Carpenter W., McGorry P., Klosterkotter J., McGuire P., Yung A. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70(1):107-120.
19. Gonzalez-Burgos G., Lewis D.A. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr. Bull. 2008, 34(5):944-961.
20. Goto N., Yoshimura R., Moriya J., Kakeda S., Ueda N., Ikenouchi-Sugita A., Umene-Nakano W., Hayashi K., Oonari N., Korogi Y., Nakamura J. Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr. Res. 2009, 112(1-3):192-193.
21. Hasan A., Wobrock T., Grefkes C., Labusga M., Levold K., Schneider-Axmann T., Falkai P., Müller H., Klosterkötter J., Bechdolf A. Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol. Psychiatry 2012, 72(9):744-751.
22. Hasan A., Falkai P., Wobrock T. Transcranial brain stimulation in schizophrenia: targeting cortical excitability, connectivity and plasticity. Curr. Med. Chem. 2013, 20(3):405-413.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
24. Kay S.R., Opler L.A., Lindenmayer J.-P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988, 23(1):99-110.
25. Kay S.R., Opler L.A., Lindenmayer J.-P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br. J. Psychiatry Suppl. 1989, 7:59-67.
26. Kegeles L.S., Mao X., Stanford A.D., Girgis R., Ojeil N., Xu X., Gil R., Slifstein M., Abi-Dargham A., Lisanby S.H. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 2012, 69(5):449-459.
27. Langguth B., Eichhammer P., Spranz C., Landgrebe M., Frick U., Sand P., Hajak G. Modulation of human motor cortex excitability by quetiapine. Psychopharmacology (Berl) 2008, 196(4):623-629.
28. Levinson A.J., Fitzgerald P.B., Favalli G., Blumberger D.M., Daigle M., Daskalakis Z.J. Evidence of cortical inhibitory deficits in major depressive disorder. Biol. Psychiatry 2010, 67(5):458-464.
29. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005, 6(4):312-324.
30. Liu S.-K., Fitzgerald P.B., Daigle M., Chen R., Daskalakis Z.J. The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia. Biol. Psychiatry 2009, 65(6):503-509.
31. Luparini M.R., Garrone B., Pazzagli M., Pinza M., Pepeu G. A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(7):1117-1127.
32. Miller T.J., McGlashan T.H., Rosen J.L., Cadenhead K., Ventura J., McFarlane W., Perkins D.O., Pearlson G.D., Woods S.W. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003, 29(4):703.
33. Nagai T., Tada M., Kirihara K., Araki T., Jinde S., Kasai K. Mismatch negativity as a "translatable" brain marker toward early intervention for psychosis: a review. Front. Psychiatry 2013, 4:115.
34. Ochoa S., Usall J., Cobo J., Labad X., Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr. Res. Treat. 2012, 2012.
35. Oranje B., Glenthøj B.Y. Clonidine normalizes levels of P50 gating in patients with schizophrenia on stable medication. Schizophr. Bull. 2013, sbt144.
36. Pascual-Leone A., Manoach D.S., Birnbaum R., Goff D.C. Motor cortical excitability in schizophrenia. Biol. Psychiatry 2002, 52(1):24-31.
37. Patel M.X., Arista I.A., Taylor M., Barnes T.R. How to compare doses of different antipsychotics: a systematic review of methods. Schizophr. Res. 2013, 149(1-3):141-148.
38. Puri B.K., Davey N.J., Ellaway P.H., Lewis S.W. An investigation of motor function in schizophrenia using transcranial magnetic stimulation of the motor cortex. Br. J. Psychiatry 1996, 169(6):690-695.
39. Radhu N., Ravindran L.N., Levinson A.J., Daskalakis Z.J. Inhibition of the cortex using transcranial magnetic stimulation in psychiatric populations: current and future directions. J. Psychiatry Neurosci. 2012, 37(4):120003.
40. Radhu N., de Jesus D.R., Ravindran L.N., Zanjani A., Fitzgerald P.B., Daskalakis Z.J. A meta-analysis of cortical inhibition and excitability using transcranial magnetic stimulation in psychiatric disorders. Clin. Neurophysiol. 2013, 124(7):1309-1320.
41. Rogasch N.C., Daskalakis Z.J., Fitzgerald P.B. Cortical inhibition, excitation, and connectivity in schizophrenia: a review of insights from transcranial magnetic stimulation. Schizophr. Bull. 2013, 40(3):685-696.
42. Roick H., von Giesen H.J., Benecke R. On the origin of the postexcitatory inhibition seen after transcranial magnetic brain stimulation in awake human subjects. Exp. Brain Res. 1993, 94(3):489-498.
43. Rowland L.M., Kontson K., West J., Edden R.A., Zhu H., Wijtenburg S.A., Holcomb H.H., Barker P.B. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr. Bull. 2013, 39(5):1096-1104.
44. Saka M.C., Atbasoglu E.C., Özgüven H.D., Sener H.Ö., Özay E. Cortical inhibition in first-degree relatives of schizophrenic patients assessed with transcranial magnetic stimulation. Int. J. Neuropsychopharmacol. 2005, 8(04):595-599.
45. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59:22-33.
46. Siebner H.R., Dressnandt J., Auer C., Conrad B. Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle Nerve 1998, 21(9):1209-1212.
47. Soubasi E., Chroni E., Gourzis P., Zisis A., Beratis S., Papathanasopoulos P. Cortical motor neurophysiology of patients with schizophrenia: a study using transcranial magnetic stimulation. Psychiatry Res. 2010, 176(2-3):132-136.
48. Spencer K.M., Nestor P.G., Niznikiewicz M.A., Salisbury D.F., Shenton M.E., McCarley R.W. Abnormal neural synchrony in schizophrenia. J. Neurosci. 2003, 23(19):7407-7411.
49. Spencer K.M., Nestor P.G., Perlmutter R., Niznikiewicz M.A., Klump M.C., Frumin M., Shenton M.E., McCarley R.W. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(49):17288-17293.
50. Werhahn K.J., Kunesch E., Noachtar S., Benecke R., Classen J. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J. Physiol. 1999, 517(Pt 2):591-597.
51. Wobrock T., Schneider M., Kadovic D., Schneider-Axmann T., Ecker U., Retz W., Rösler M., Falkai P. Reduced cortical inhibition in first-episode schizophrenia. Schizophr. Res. 2008, 105(1-3):252-261.
52. Woods S.W., Carlson J.P., McGlashan T.H. DSM-5 and the 'psychosis risk syndrome': the DSM-5 proposal is better than DSM-IV. Psychosis 2010, 2(3):187-190.
53. Wu C., Sun D. GABA receptors in brain development, function, and injury. Metab. Brain Dis. 2014.
54. Yung A.R., Yuen H.P., McGorry P.D., Phillips L.J., Kelly D., Dell'Olio M., Francey S.M., Cosgrave E.M., Killackey E., Stanford C., Godfrey K., Buckby J. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust. N. Z. J. Psychiatry 2005, 39(11-12):964-971. 10.1007/s11011-014-9560-1.
55. Zhang T., Li H., Woodberry K.A., Seidman L.J., Zheng L., Li H., Zhao S., Tang Y., Guo Q., Lu X. Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study. Schizophr. Res. 2013, 152(2-3):391-399.
56. Ziemann U. TMS and drugs. Clin. Neurophysiol. 2004, 115(8):1717-1729.
57. Ziemann U., Lonnecker S., Steinhoff B.J., Paulus W. The effect of lorazepam on the motor cortical excitability in man. Exp. Brain Res. 1996, 109(1):127-135.
58. Ziemann U., Lonnecker S., Steinhoff B.J., Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann. Neurol. 1996, 40(3):367-378.
59. Ziemann U., Tergau F., Bruns D., Baudewig J., Paulus W. Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. Electroencephalogr Clin. Neurophysiol. 1997, 105(6):430-437.